PUBLISHER: TechSci Research | PRODUCT CODE: 1968564
PUBLISHER: TechSci Research | PRODUCT CODE: 1968564
Monoclonal Antibodies In Veterinary Health Market - Global Industry Size, Share, Trends, Opportunity & Forecast, Segmented By Animal Type, By Application, End-User, By Region & Competition, 2021-2031F
We offer 8 hour analyst time for an additional research. Please contact us for the details.
The Global Monoclonal Antibodies In Veterinary Health Market is projected to expand from USD 924.12 Million in 2025 to USD 2206.48 Million by 2031, registering a CAGR of 15.61%. These specialized biologic therapies are engineered to target specific proteins, such as receptors or cytokines, within disease pathways to treat animal conditions like dermatitis, cancer, and osteoarthritis. The market is primarily driven by the increasing prevalence of chronic diseases in pets and the trend toward pet humanization, which fuels demand for advanced, species-specific treatments with fewer side effects than traditional drugs. As noted by the American Veterinary Medical Association, the U.S. dog population reached 87.3 million in 2025, highlighting a growing patient base for these therapeutics.
| Market Overview | |
|---|---|
| Forecast Period | 2027-2031 |
| Market Size 2025 | USD 924.12 Million |
| Market Size 2031 | USD 2206.48 Million |
| CAGR 2026-2031 | 15.61% |
| Fastest Growing Segment | Dermatology |
| Largest Market | North America |
Despite the strong potential for growth, the market encounters significant challenges due to the high costs associated with developing and manufacturing biologic drugs. These steep production expenses result in higher prices for pet owners, which restricts accessibility and adoption in lower-income demographics or price-sensitive regions. Consequently, while the clinical advantages of monoclonal antibodies are clear, the financial burden remains a major obstacle to achieving widespread global market penetration.
Market Driver
The rising incidence of chronic and infectious diseases in animals acts as a primary catalyst for the adoption of monoclonal antibodies, especially for long-term pain management in conditions like osteoarthritis. Unlike traditional NSAIDs, which can cause adverse effects over time, monoclonal antibodies neutralize specific proteins to provide pain relief with a better safety profile. This shift is highlighted by Zoetis Inc.'s February 2025 financial results, which reported an 80% operational growth in their osteoarthritis pain franchise, confirming that veterinarians are increasingly prioritizing biologic interventions for chronic ailments in aging pets.
Simultaneously, the increasing penetration of pet health insurance plays a crucial role in sustaining market growth by offsetting the high costs of these advanced treatments. Since monoclonal antibodies are premium products, insurance coverage ensures patient adherence and broader accessibility. The willingness of owners to spend on healthcare is reflected in American Pet Products Association data from March 2025, showing U.S. pet industry expenditures reached $152 billion in 2024. Additionally, the North American Pet Health Insurance Association reported in June 2025 that gross written premiums in the U.S. surpassed a record $4.7 billion in 2024, demonstrating strong financial support for high-value veterinary care.
Market Challenge
The elevated costs associated with developing and manufacturing biologic drugs create a substantial economic barrier that limits the expansion of the Global Monoclonal Antibodies In Veterinary Health Market. Because these therapies require complex engineering and production, the premium pricing is typically passed on to the consumer. This leads to a discrepancy between clinical availability and practical accessibility, as veterinarians are often hesitant to prescribe effective but expensive treatments to clients with limited funds. As a result, many potential customers depend on lower-cost conventional pharmaceuticals, reducing the market share for these advanced biologics.
This price sensitivity directly affects veterinary visit frequency and the uptake of high-value treatments. According to Animal Medicines Australia in 2025, 30% of dog owners and 22% of cat owners who reduced their veterinary visits cited affordability as the primary reason. This data underscores a critical friction point where economic constraints prevent access to necessary healthcare. As long as these treatments remain financially out of reach for average-income households, the market will struggle to convert rising disease prevalence into sustained revenue growth.
Market Trends
The market is expanding its therapeutic focus beyond osteoarthritis and dermatology, with a notable surge in monoclonal antibodies targeting infectious diseases. Developers are validating biologics that neutralize viral threats, providing targeted alternatives to supportive care for high-mortality conditions. For example, treatments for canine parvovirus now combat the virus directly rather than just managing symptoms. In October 2024, Elanco Animal Health released data showing that 93% of puppies treated with their Canine Parvovirus Monoclonal Antibody survived, marking a significant improvement in reducing mortality rates.
In addition, strategic licensing and co-development partnerships are increasing as major pharmaceutical companies seek to integrate novel biologic platforms from agile biotech firms. These collaborations allow market leaders to bypass discovery bottlenecks and access proprietary technologies, such as half-life extension. A key example occurred in July 2024, when Dechra Pharmaceuticals agreed to acquire Invetx for up to $520 million, thereby gaining access to a pipeline of specialized monoclonal antibodies for chronic diseases in companion animals.
Key Market Players
- Zoetis Inc.
- Elanco Animal Health Incorporated
- Boehringer Ingelheim Animal Health GmbH
- Merck & Co., Inc.
- Virbac S.A.
- Ceva Sante Animale S.A.
- IDEXX Laboratories, Inc.
- Thermo Fisher Scientific Inc.
- Vetoquinol S.A.
- Aratana Therapeutics, Inc.
Report Scope
In this report, the Global Monoclonal Antibodies In Veterinary Health Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
Monoclonal Antibodies In Veterinary Health Market, By Animal Type
- Dogs
- Others
Monoclonal Antibodies In Veterinary Health Market, By Application
- Dermatology
- Pain
- Others
Monoclonal Antibodies In Veterinary Health Market, By Region
- North America
- United States
- Canada
- Mexico
- Europe
- France
- United Kingdom
- Italy
- Germany
- Spain
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- South America
- Brazil
- Argentina
- Colombia
- Middle East & Africa
- South Africa
- Saudi Arabia
- UAE
Competitive Landscape
Company Profiles: Detailed analysis of the major companies present in the Global Monoclonal Antibodies In Veterinary Health Market.
Available Customizations:
Global Monoclonal Antibodies In Veterinary Health Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Company Information
- Detailed analysis and profiling of additional market players (up to five).
Table of Contents
1. Product Overview
- 1.1. Market Definition
- 1.2. Scope of the Market
- 1.2.1. Markets Covered
- 1.2.2. Years Considered for Study
- 1.2.3. Key Market Segmentations
2. Research Methodology
- 2.1. Objective of the Study
- 2.2. Baseline Methodology
- 2.3. Key Industry Partners
- 2.4. Major Association and Secondary Sources
- 2.5. Forecasting Methodology
- 2.6. Data Triangulation & Validation
- 2.7. Assumptions and Limitations
3. Executive Summary
- 3.1. Overview of the Market
- 3.2. Overview of Key Market Segmentations
- 3.3. Overview of Key Market Players
- 3.4. Overview of Key Regions/Countries
- 3.5. Overview of Market Drivers, Challenges, Trends
4. Voice of Customer
5. Global Monoclonal Antibodies In Veterinary Health Market Outlook
- 5.1. Market Size & Forecast
- 5.1.1. By Value
- 5.2. Market Share & Forecast
- 5.2.1. By Animal Type (Dogs, Others)
- 5.2.2. By Application (Dermatology, Pain, Others)
- 5.2.3. By Region
- 5.2.4. By Company (2025)
- 5.3. Market Map
6. North America Monoclonal Antibodies In Veterinary Health Market Outlook
- 6.1. Market Size & Forecast
- 6.1.1. By Value
- 6.2. Market Share & Forecast
- 6.2.1. By Animal Type
- 6.2.2. By Application
- 6.2.3. By Country
- 6.3. North America: Country Analysis
- 6.3.1. United States Monoclonal Antibodies In Veterinary Health Market Outlook
- 6.3.1.1. Market Size & Forecast
- 6.3.1.1.1. By Value
- 6.3.1.2. Market Share & Forecast
- 6.3.1.2.1. By Animal Type
- 6.3.1.2.2. By Application
- 6.3.1.1. Market Size & Forecast
- 6.3.2. Canada Monoclonal Antibodies In Veterinary Health Market Outlook
- 6.3.2.1. Market Size & Forecast
- 6.3.2.1.1. By Value
- 6.3.2.2. Market Share & Forecast
- 6.3.2.2.1. By Animal Type
- 6.3.2.2.2. By Application
- 6.3.2.1. Market Size & Forecast
- 6.3.3. Mexico Monoclonal Antibodies In Veterinary Health Market Outlook
- 6.3.3.1. Market Size & Forecast
- 6.3.3.1.1. By Value
- 6.3.3.2. Market Share & Forecast
- 6.3.3.2.1. By Animal Type
- 6.3.3.2.2. By Application
- 6.3.3.1. Market Size & Forecast
- 6.3.1. United States Monoclonal Antibodies In Veterinary Health Market Outlook
7. Europe Monoclonal Antibodies In Veterinary Health Market Outlook
- 7.1. Market Size & Forecast
- 7.1.1. By Value
- 7.2. Market Share & Forecast
- 7.2.1. By Animal Type
- 7.2.2. By Application
- 7.2.3. By Country
- 7.3. Europe: Country Analysis
- 7.3.1. Germany Monoclonal Antibodies In Veterinary Health Market Outlook
- 7.3.1.1. Market Size & Forecast
- 7.3.1.1.1. By Value
- 7.3.1.2. Market Share & Forecast
- 7.3.1.2.1. By Animal Type
- 7.3.1.2.2. By Application
- 7.3.1.1. Market Size & Forecast
- 7.3.2. France Monoclonal Antibodies In Veterinary Health Market Outlook
- 7.3.2.1. Market Size & Forecast
- 7.3.2.1.1. By Value
- 7.3.2.2. Market Share & Forecast
- 7.3.2.2.1. By Animal Type
- 7.3.2.2.2. By Application
- 7.3.2.1. Market Size & Forecast
- 7.3.3. United Kingdom Monoclonal Antibodies In Veterinary Health Market Outlook
- 7.3.3.1. Market Size & Forecast
- 7.3.3.1.1. By Value
- 7.3.3.2. Market Share & Forecast
- 7.3.3.2.1. By Animal Type
- 7.3.3.2.2. By Application
- 7.3.3.1. Market Size & Forecast
- 7.3.4. Italy Monoclonal Antibodies In Veterinary Health Market Outlook
- 7.3.4.1. Market Size & Forecast
- 7.3.4.1.1. By Value
- 7.3.4.2. Market Share & Forecast
- 7.3.4.2.1. By Animal Type
- 7.3.4.2.2. By Application
- 7.3.4.1. Market Size & Forecast
- 7.3.5. Spain Monoclonal Antibodies In Veterinary Health Market Outlook
- 7.3.5.1. Market Size & Forecast
- 7.3.5.1.1. By Value
- 7.3.5.2. Market Share & Forecast
- 7.3.5.2.1. By Animal Type
- 7.3.5.2.2. By Application
- 7.3.5.1. Market Size & Forecast
- 7.3.1. Germany Monoclonal Antibodies In Veterinary Health Market Outlook
8. Asia Pacific Monoclonal Antibodies In Veterinary Health Market Outlook
- 8.1. Market Size & Forecast
- 8.1.1. By Value
- 8.2. Market Share & Forecast
- 8.2.1. By Animal Type
- 8.2.2. By Application
- 8.2.3. By Country
- 8.3. Asia Pacific: Country Analysis
- 8.3.1. China Monoclonal Antibodies In Veterinary Health Market Outlook
- 8.3.1.1. Market Size & Forecast
- 8.3.1.1.1. By Value
- 8.3.1.2. Market Share & Forecast
- 8.3.1.2.1. By Animal Type
- 8.3.1.2.2. By Application
- 8.3.1.1. Market Size & Forecast
- 8.3.2. India Monoclonal Antibodies In Veterinary Health Market Outlook
- 8.3.2.1. Market Size & Forecast
- 8.3.2.1.1. By Value
- 8.3.2.2. Market Share & Forecast
- 8.3.2.2.1. By Animal Type
- 8.3.2.2.2. By Application
- 8.3.2.1. Market Size & Forecast
- 8.3.3. Japan Monoclonal Antibodies In Veterinary Health Market Outlook
- 8.3.3.1. Market Size & Forecast
- 8.3.3.1.1. By Value
- 8.3.3.2. Market Share & Forecast
- 8.3.3.2.1. By Animal Type
- 8.3.3.2.2. By Application
- 8.3.3.1. Market Size & Forecast
- 8.3.4. South Korea Monoclonal Antibodies In Veterinary Health Market Outlook
- 8.3.4.1. Market Size & Forecast
- 8.3.4.1.1. By Value
- 8.3.4.2. Market Share & Forecast
- 8.3.4.2.1. By Animal Type
- 8.3.4.2.2. By Application
- 8.3.4.1. Market Size & Forecast
- 8.3.5. Australia Monoclonal Antibodies In Veterinary Health Market Outlook
- 8.3.5.1. Market Size & Forecast
- 8.3.5.1.1. By Value
- 8.3.5.2. Market Share & Forecast
- 8.3.5.2.1. By Animal Type
- 8.3.5.2.2. By Application
- 8.3.5.1. Market Size & Forecast
- 8.3.1. China Monoclonal Antibodies In Veterinary Health Market Outlook
9. Middle East & Africa Monoclonal Antibodies In Veterinary Health Market Outlook
- 9.1. Market Size & Forecast
- 9.1.1. By Value
- 9.2. Market Share & Forecast
- 9.2.1. By Animal Type
- 9.2.2. By Application
- 9.2.3. By Country
- 9.3. Middle East & Africa: Country Analysis
- 9.3.1. Saudi Arabia Monoclonal Antibodies In Veterinary Health Market Outlook
- 9.3.1.1. Market Size & Forecast
- 9.3.1.1.1. By Value
- 9.3.1.2. Market Share & Forecast
- 9.3.1.2.1. By Animal Type
- 9.3.1.2.2. By Application
- 9.3.1.1. Market Size & Forecast
- 9.3.2. UAE Monoclonal Antibodies In Veterinary Health Market Outlook
- 9.3.2.1. Market Size & Forecast
- 9.3.2.1.1. By Value
- 9.3.2.2. Market Share & Forecast
- 9.3.2.2.1. By Animal Type
- 9.3.2.2.2. By Application
- 9.3.2.1. Market Size & Forecast
- 9.3.3. South Africa Monoclonal Antibodies In Veterinary Health Market Outlook
- 9.3.3.1. Market Size & Forecast
- 9.3.3.1.1. By Value
- 9.3.3.2. Market Share & Forecast
- 9.3.3.2.1. By Animal Type
- 9.3.3.2.2. By Application
- 9.3.3.1. Market Size & Forecast
- 9.3.1. Saudi Arabia Monoclonal Antibodies In Veterinary Health Market Outlook
10. South America Monoclonal Antibodies In Veterinary Health Market Outlook
- 10.1. Market Size & Forecast
- 10.1.1. By Value
- 10.2. Market Share & Forecast
- 10.2.1. By Animal Type
- 10.2.2. By Application
- 10.2.3. By Country
- 10.3. South America: Country Analysis
- 10.3.1. Brazil Monoclonal Antibodies In Veterinary Health Market Outlook
- 10.3.1.1. Market Size & Forecast
- 10.3.1.1.1. By Value
- 10.3.1.2. Market Share & Forecast
- 10.3.1.2.1. By Animal Type
- 10.3.1.2.2. By Application
- 10.3.1.1. Market Size & Forecast
- 10.3.2. Colombia Monoclonal Antibodies In Veterinary Health Market Outlook
- 10.3.2.1. Market Size & Forecast
- 10.3.2.1.1. By Value
- 10.3.2.2. Market Share & Forecast
- 10.3.2.2.1. By Animal Type
- 10.3.2.2.2. By Application
- 10.3.2.1. Market Size & Forecast
- 10.3.3. Argentina Monoclonal Antibodies In Veterinary Health Market Outlook
- 10.3.3.1. Market Size & Forecast
- 10.3.3.1.1. By Value
- 10.3.3.2. Market Share & Forecast
- 10.3.3.2.1. By Animal Type
- 10.3.3.2.2. By Application
- 10.3.3.1. Market Size & Forecast
- 10.3.1. Brazil Monoclonal Antibodies In Veterinary Health Market Outlook
11. Market Dynamics
- 11.1. Drivers
- 11.2. Challenges
12. Market Trends & Developments
- 12.1. Merger & Acquisition (If Any)
- 12.2. Product Launches (If Any)
- 12.3. Recent Developments
13. Global Monoclonal Antibodies In Veterinary Health Market: SWOT Analysis
14. Porter's Five Forces Analysis
- 14.1. Competition in the Industry
- 14.2. Potential of New Entrants
- 14.3. Power of Suppliers
- 14.4. Power of Customers
- 14.5. Threat of Substitute Products
15. Competitive Landscape
- 15.1. Zoetis Inc.
- 15.1.1. Business Overview
- 15.1.2. Products & Services
- 15.1.3. Recent Developments
- 15.1.4. Key Personnel
- 15.1.5. SWOT Analysis
- 15.2. Elanco Animal Health Incorporated
- 15.3. Boehringer Ingelheim Animal Health GmbH
- 15.4. Merck & Co., Inc.
- 15.5. Virbac S.A.
- 15.6. Ceva Sante Animale S.A.
- 15.7. IDEXX Laboratories, Inc.
- 15.8. Thermo Fisher Scientific Inc.
- 15.9. Vetoquinol S.A.
- 15.10. Aratana Therapeutics, Inc.
16. Strategic Recommendations
17. About Us & Disclaimer
